Related Experiment Video
Updated: Mar 3, 2026
09:44
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
3.5K
Weight loss in obese girls with polycystic ovarian syndrome is associated with a decrease in Anti-Muellerian Hormone
Thomas Reinehr1, Alexandra Kulle2, Juliane Rothermel1
1Department of Pediatric Endocrinology, Diabetes, and Nutrition Medicine, Vestische Hospital for Children and Adolescents, University of Witten/Herdecke, Datteln, Germany.
Clinical Endocrinology
|April 23, 2017
Summary
Anti-Müllerian Hormone (AMH) levels are higher in obese adolescent girls with Polycystic Ovary Syndrome (PCOS). Weight loss helped normalize AMH, indicating its role in PCOS and hyperandrogenism.
Area of Science:
- Reproductive Endocrinology
- Pediatric Endocrinology
- Metabolic Disorders
Background:
- Anti-Müllerian Hormone (AMH) is a marker for antral follicles, implicated in polycystic ovarian syndrome (PCOS) hyperandrogenism.
- AMH's role in diagnosing PCOS in adolescents warrants further investigation.
Purpose of the Study:
- To investigate longitudinal changes in AMH concentrations in obese adolescent girls with and without PCOS.
- To assess the relationship between AMH and hyperandrogenism markers in this population.
Main Methods:
- A 1-year longitudinal study involving 40 obese girls (aged 13-16 years), with 50% diagnosed with PCOS.
- Participants were matched for age, BMI, and weight change.
- Measurements included AMH, gonadotropins, androgens (androstenedione, testosterone), estradiol, and sex hormone-binding globulin (SHBG).
Main Results:
- Obese girls with PCOS had significantly higher AMH levels (5.8±3.1 ng/mL) compared to controls (2.4±1.4 ng/mL).
- Weight loss in PCOS girls was associated with a significant decrease in AMH levels (P=.045).
- AMH showed significant cross-sectional and longitudinal associations with testosterone and luteinizing hormone (LH).
Conclusions:
- AMH levels are elevated in adolescent girls with PCOS and can normalize with weight loss.
- AMH is a reliable indicator of hyperandrogenism in adolescent PCOS, both cross-sectionally and longitudinally.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
326
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
326
01:24Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
02:07Oogenesis
70.7K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
70.7K
01:30Hormonal Control of the Ovarian Cycle
7.2K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
7.2K
01:21Drug Dosing: Obese Patients
317
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
317
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
257
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
257